US 11596688
Predicting outcome of treatment with an anti-α4β7 integrin antibody
granted A61KA61K2039/505A61K2039/54
Quick answer
US patent 11596688 (Predicting outcome of treatment with an anti-α4β7 integrin antibody) held by Takeda Pharmaceutical Company Limited expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 8
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K39/395, A61P